肝脏特异性氧酶-1通过肝细胞癌的代谢重编程减轻调节性T细胞驱动的免疫抑制
Zhou Lu1,2,3, Huanchen Shi4, Rongshan Gao4
1Institute of Clinical Sciences, Zhongshan Hospital, Fudan University, Shanghai, China. lu.zhou1@zs-hospital.sh.cn.
Nature communications
|December 12, 2025
概括
氧酶-1 (PON1) 通过调节新陈代谢和减少免疫抑制来抑制肝癌. 增强PON1在治疗肝细胞癌 (HCC) 和改善免疫疗法反应方面表现有前途.
科学领域:
- 肝胆道研究 肝胆道研究
- 免疫代谢过程中的免疫代谢.
- 在瘤学瘤学.
背景情况:
- 氧酶-1 (PON1) 是肝脏表达的,在肝脏疾病中具有已知的作用.
- 在肝细胞癌 (HCC) 中PON1的特定功能和机制尚不清楚.
研究的目的:
- 阐明PON1在调节瘤微环境和HCC进展中的作用和机制.
- 调查PON1作为HCC的潜在治疗点.
主要方法:
- 研究了PON1在调节缺氧诱导因子α (HIF-1α) 的作用,通过Von Hippel-Lindau蛋白 (VHL) 介导的降解.
- 评估了PON1对乳酸产生和调控性T (Treg) 细胞积累的影响.
- 评估了PON1表达和患者预后之间的相关性.
- 在临床前的HCC模型中测试了复合PON1 (rPON1) 和PON1增强剂 (quercetin) 的疗效,包括与抗PD-1疗法结合治疗.
主要成果:
- PON1充当代谢调节剂,抵消Treg细胞介导的HCC免疫抑制.
- PON1促进HIF-1α的降解,减少乳酸的产生和Treg细胞的透.
- 患者中较高的PON1表达与更好的HCC预后相关.
- 在小鼠中,rPON1抑制了瘤生长,而氨酸诱导的PON1增强使HCC对抗PD-1治疗敏感.
结论:
- 通过调节乳酸代谢和缓解免疫抑制,PON1抑制了HCC的进展.
- 向PON1代表了肝细胞癌的一个有前途的治疗策略.
- 调节PON1可以提高现有的免疫疗法对HCC的疗效.
相关概念视频
Liver Regeneration
4.2K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.2K
Peroxisomes
19.9K
Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
19.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
200
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
200
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169


